Literature DB >> 24647989

Hypovitaminosis D in primary hyperparathyroidism: to treat or not to treat? That is the question.

Salvatore Minisola1, Elisabetta Romagnoli, Alfredo Scillitani, Sudhakar D Rao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24647989     DOI： 10.1007/s40618-014-0060-2

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  18 in total

1.  Metabolic inactivation of vitamin D is enhanced in primary hyperparathyroidism.

Authors:  M R Clements; M Davies; D R Fraser; G A Lumb; E B Mawer; P H Adams
Journal:  Clin Sci (Lond)       Date:  1987-12       Impact factor: 6.124

Review 2.  Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature.

Authors:  Viral N Shah; Chirag S Shah; Sanjay K Bhadada; D Sudhakar Rao
Journal:  Clin Endocrinol (Oxf)       Date:  2014-01-28       Impact factor: 3.478

Review 3.  Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism.

Authors:  Jens Bollerslev; Claudio Marcocci; Manuel Sosa; Jörgen Nordenström; Roger Bouillon; Leif Mosekilde
Journal:  Eur J Endocrinol       Date:  2011-09-29       Impact factor: 6.664

4.  Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications.

Authors:  D S Rao; M Honasoge; G W Divine; E R Phillips; M W Lee; M R Ansari; G B Talpos; A M Parfitt
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

5.  Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism.

Authors:  B Moosgaard; P Vestergaard; L Heickendorff; F Melsen; P Christiansen; L Mosekilde
Journal:  Clin Endocrinol (Oxf)       Date:  2005-11       Impact factor: 3.478

6.  Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency.

Authors:  M Luisa Isidro; Belén Ruano
Journal:  Endocrine       Date:  2009-07-14       Impact factor: 3.633

7.  Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency.

Authors:  Andrew Grey; Jenny Lucas; Anne Horne; Greg Gamble; James S Davidson; Ian R Reid
Journal:  J Clin Endocrinol Metab       Date:  2005-01-11       Impact factor: 5.958

8.  Serum carboxy-terminal propeptide of human type I procollagen in patients with primary hyperparathyroidism: studies in basal conditions and after parathyroid surgery.

Authors:  S Minisola; E Romagnoli; L Scarnecchia; R Rosso; M T Pacitti; A Scarda; G Mazzuoli
Journal:  Eur J Endocrinol       Date:  1994-06       Impact factor: 6.664

9.  Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial.

Authors:  Lars Rolighed; Lars Rejnmark; Tanja Sikjaer; Lene Heickendorff; Peter Vestergaard; Leif Mosekilde; Peer Christiansen
Journal:  J Clin Endocrinol Metab       Date:  2014-01-13       Impact factor: 5.958

Review 10.  Perspective on assessment of vitamin D nutrition.

Authors:  D S Rao
Journal:  J Clin Densitom       Date:  1999       Impact factor: 2.963
View more
  3 in total

Review 1.  A reappraisal of vitamin D effect on non-skeletal targets and mortality.

Authors:  S Minisola; C Cipriani; M Cilli; A Scillitani; J Pepe
Journal:  J Endocrinol Invest       Date:  2015-09-10       Impact factor: 4.256

2.  Italian Society of Endocrinology Consensus Statement: definition, evaluation and management of patients with mild primary hyperparathyroidism.

Authors:  C Marcocci; M L Brandi; A Scillitani; S Corbetta; A Faggiano; L Gianotti; S Migliaccio; S Minisola
Journal:  J Endocrinol Invest       Date:  2015-03-28       Impact factor: 4.256

3.  Changes in bone mineral density after parathyroidectomy in patients with moderate to severe primary hyperparathyroidism.

Authors:  Shuai Lu; Maoqi Gong; Yejun Zha; Aimin Cui; Chen Chen; Hao Yang; Weitong Sun; Kehan Hua; Wei Tian; Xieyuan Jiang
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.